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We have previously demonstrated that swine vaccinated with one dose of a replication-defective human adenovirus type 5 (Ad5) vector
containing the capsid and 3C proteinase coding regions of foot-and-mouth disease virus (FMDV) were protected when challenged 7 days
later with homologous virus. In the current study, we have extended this approach to cattle, the most economically important animals
susceptible to FMD. Five cattle were vaccinated with the Ad5-FMDV subunit vaccine and these animals and 2 co-housed control animals
were challenged intradermolingually 7 days later. Both control animals developed typical signs of FMD including fever and vesicular lesions
on all 4 feet. All 5 vaccinated animals were protected against disseminated disease.
Published by Elsevier Inc.Keywords: Foot-and-mouth disease virus; Replication-defective human adenovirus; Subunit vaccineIntroduction
Foot-and-mouth disease (FMD) is a highly contagious
disease of cloven-hoofed animals including cattle, swine,
sheep, and goats that rapidly replicates in the host and spreads
to in-contact susceptible animals. Disease incursions in
previously FMD-free countries, such as in the United
Kingdom (UK) in 2001 (Knowles et al., 2001), are controlled
by inhibition of susceptible animal movement, slaughter of
infected and in-contact animals, and decontamination. The
use of vaccination is often a decision of last resort mainly
because of the adverse economic consequences of vaccina-
tion as compared to slaughter. Countries that slaughter
infected and in-contact animals can regain FMD-free status0042-6822/$ - see front matter. Published by Elsevier Inc.
doi:10.1016/j.virol.2005.04.014
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E-mail address: mgrubman@piadc.ars.usda.gov (M.J. Grubman).by documenting absence of disease for 3 months after the last
case, while countries that vaccinate and do not slaughter
these animals must wait a year to regain this status. The 2001
FMD outbreak in the Netherlands that occurred as a result of
the UK episode was controlled by the above protocols as well
as ring vaccination, although all vaccinated animals were
subsequently slaughtered allowing the Netherlands to avoid a
delay in regaining FMD-free status (Pluimers et al., 2002).
However, the large number of animals slaughtered in the UK
and the Netherlands, the environmental problems raised by
the need to eliminate these animals, and the public concern
about this approach have affected the policy of the World
Organization for Animal Health, Office International des
Epizooties (OIE), as well as the European Union, and the
United Kingdom (Anonymous, 2002; Scudamore and Harris,
2002). As a result, new regulations have been approved
which result in a more favorable economic treatment of05) 205 – 209
Table 1
Serum neutralizing antibody response after vaccination with Ad5-A24 and
challenge with FMDVA24
Animal # Vaccinea PRN70
b dpcc
7 4 0 4 7 14 21 28
17 Ad5-VSVG <8 <8 <8 16 4096 4096 4096 4096
33 Ad5-VSVG <8 <8 <8 32 4096 4096 4096 4096
20 Ad5-A24 <8 <8 32 128 2048 1024 1024 1024
25 Ad5-A24 <8 <8 16 256 1024 1024 1024 1024
26 Ad5-A24 <8 <8 16 32 1024 1024 2048 1024
27 Ad5-A24 <8 <8 128 512 2048 1024 1024 1024
28 Ad5-A24 <8 <8 16 32 512 512 512 512
a Bovines were vaccinated with 5  109 pfu/animal Ad5-VSVG or Ad5-
A24 and challenged 7 days later.
b FMDV-specific neutralizing antibody titer reported as the serum
dilution yielding a 70% reduction in the number of plaques.
c Days postchallenge.
Rapid Communication206countries which vaccinate and do not slaughter vaccinated
animals (Anonymous, 2004). These countries can now regain
FMD-free status 6 months after the last case has been
reported rather than 1 year later.
The current FMD vaccine is a chemically inactivated
whole virus antigen that, depending upon the manufacturer,
contains varying degrees of contaminating viral nonstruc-
tural proteins (NSP) (Doel, 2003). As a result, it can be
difficult to distinguish vaccinated from infected animals
using currently approved diagnostic tests. Therefore, dis-
ease-free countries prohibit the importation of susceptible
animals or animal products from countries that have FMD or
that vaccinate to control the disease. We have attempted to
develop novel FMD vaccines that can avoid this concern
and, with one inoculation, rapidly protect susceptible
animals. These novel vaccines contain only the portion of
the viral genome coding for the viral structural proteins and
3C, the NSP required for virus capsid formation (Mayr et al.,
1999). Thus, animals inoculated with this immunogen can be
unequivocally distinguished from infected or convalescent
animals using currently approved diagnostic assays (Mayr et
al., 1999; Mayr et al., 2001), as well as with diagnostic
assays using the most immunogenic NSP, 3D. We have
demonstrated that one inoculation with this immunogen,
empty viral capsids from FMDV serotype A24 Cruzeiro,
delivered by a replication-defective human adenovirus type 5
vector (Ad5-A24), can protect swine at 7, 14, or 42 days
postvaccination (dpv) when challenged by direct inoculation
in the heel bulb with virulent homologous virus (Moraes
et al., 2002). Since cattle are the most economically
important livestock susceptible to FMDV, we have initiated
studies to determine the potency and efficacy of this vector
system in cattle. In a preliminary experiment, we demon-
strated that two inoculations of Ad5-A24 induce a very
significant FMDV-specific neutralizing antibody response
and protect cattle challenged 2 weeks postboost (Grubman
and Mason, 2002). In the current study, we have examined
the ability of this vector, in one dose, to protect cattle
challenged intradermolingually 7 dpv.Results
Vaccination with Ad5-A24
Five cattle were each inoculated intramuscularly (IM)
with 5  109 pfu Ad5-A24 and two control animals were
inoculated with the same dose of an Ad5 vector containing
the glycoprotein gene of vesicular stomatitis virus New
Jersey (Ad5-VSVG). All 5 Ad5-A24-inoculated animals
developed a detectable FMDV-specific neutralizing anti-
body response (PRN70) by 7 dpv (Table 1). Four of these
animals had low titers, between 16 and 32, while bovine 27
developed a more significant PRN70, i.e., 128. The two
control animals vaccinated with Ad5-VSVG had no
detectable FMDV-specific neutralizing antibody response.Challenge with A24
Seven dpv, all animals were challenged by intradermal
inoculation at two sites in the tongue with 20,000 bovine
infectious doses (BID50) of A24 Cruzeiro. Both control
animals, #33 and #17, developed a fever (temperature 40 -C
or higher for more than 1 consecutive day) by 2 or 4 days
postchallenge (dpc) which lasted for an additional 1 to 2
days, while none of the Ad5-A24-vaccinated animals had a
temperature above 39 -C (Fig. 1A).
All 7 animals developed a vesicle at the site of inoculation.
In the 5 Ad5-A24-vaccinated animals, the vesicle was self-
limited and did not increase after 2 dpc, while in the 2 control
animals the vesicle expanded and eventually ruptured. By
day 2 postchallenge, both control animals developed lesions
at secondary sites of replication including the feet and by 3–5
dpc the disease was more severe with lesion scores of 9 and
10 out of a maximum score of 11 (Fig. 1B). Only 1 of the
Ad5-A24-vaccinated animals, #26, developed a lesion. This
single lesion was detectable by 4 dpc and was present on the
dental pad (Fig. 1B).
Both control animals had viremia from days 1–3
postchallenge with a peak of 103 to 104 pfu/ml on day 2
postchallenge (Fig. 1C). Viremia was not detectable in any
of the Ad5-A24-vaccinated animals from days 1 to 7
postchallenge (Fig. 1C). The control animals seroconverted
by 4 dpc and developed a significant FMDV-specific
neutralizing antibody response by 7 dpc. The neutralizing
antibody response of all the Ad5-A24-vaccinated animals
increased after challenge, but was 2- to 8-fold lower than the
control animals (Table 1).
All animals were negative by 3ABC ELISA prior to the
start of the experiment and remained negative at the day of
challenge (7 dpv). The control animals and Ad5-A24-
vaccinated animals #25, 26, and 28 became 3ABC-ELISA
positive by 14 dpc while #20 became positive by 21 dpc and
#27 by 28 dpc (Table 2). All animals were negative for
antibodies against NSP, i.e., 3CD, 3D, and 2C, by radio-
immunoprecipitation (RIP) on the day of challenge, but at
28 dpc the only one that remained negative was bovine #20
Table 2
Antibody response against NSP after vaccination with Ad5-A24 and
challenge with FMDVA24
Animal # Vaccinea 3ABC-ELISAb dpcc
7 0 7 14 21 28
17 Ad5-VSVG    + + +
33 Ad5-VSVG    + + +
20 Ad5-A24     + +
25 Ad5-A24    + + +
26 Ad5-A24    + + +
27 Ad5-A24      +
28 Ad5-A24    + + +
a Bovines were vaccinated with 5  109 pfu/animal Ad5-VSVG or Ad5-
A24 and challenged 7 days later.
b 3ABC-ELISA negative () or positive (+).
c Days postchallenge.
Fig. 1. Effect of FMDV challenge on animals inoculated with Ad5-A24 and
control animals inoculated with Ad5-VSVG. Data are shown from the day
of challenge up to 7 dpc. Animals were challenged intradermolingually
with 20,000 BID50 of A24. The control animals are represented by the Ad5-
VSVG group, #17 ( ) and #33 ( ). Animals vaccinated with Ad5-
A24 are: #20 ( ), #25 ( ), #26 ( ), #27 ( ), and #28 ( ).
In panel A, rectal temperatures were collected from before vaccination until
28 dpc. Temperatures at or above the line shown at 40 -C for two or more
consecutive days are defined as a fever. No fever was detected in the days
not shown. In panel B, animals were monitored for clinical signs up to 10
dpc, but changes were not seen between days 7 and 10 postchallenge.
Eleven is the highest possible clinical score. In panel C, viremia was
determined by plaque assay, 5 pfu/ml is the lowest detectable level.
Rapid Communication 207(Fig. 2, lane 10), while #25 was only weakly positive for 3D
(Fig. 2, lane 11).Fig. 2. Examination by RIP of 0 and 28 dpc serum from control (#17 and
#33) or Ad5-A24-vaccinated animals (#20, #25–28) for antibody response
against FMDV structural and NSP. [35S]-Methionine-labeled cell lysates
from FMDV A24-infected BHK-21 cells were immunoprecipitated with
various sera. Lanes 1 and 9: convalescent serum from an FMDV infected
bovine; lanes 2–6: 0 dpc sera from the animals vaccinated with Ad5-A24
(#20, 25–28); lanes 7–8: 0 dpc sera from the control animals vaccinated
with Ad5-VSVG (#17 and #33); lanes 10–14: 28 dpc sera from the animals
vaccinated with Ad5-A24 (#20, 25–28); lanes 15–16: 28 dpc sera from the
control animals vaccinated with Ad5-VSVG (#17 and #33). Immunopre-
cipitated samples were examined by SDS–PAGE on a 15% gel.Discussion
We have demonstrated that cattle vaccinated with one
dose of an Ad5-A24 subunit vaccine were protected, 7 dpv,
from clinical disease after direct inoculation challenge with
virulent FMDVA24 as well as contact with actively infected
animals. The vaccinated animals did not develop fever or
viremia after challenge. In contrast, the two control animalsin the same room developed fever, viremia, and vesicular
lesions on all 4 feet. Although one vaccinated animal
developed a dental pad lesion by 4 dpc, the disease did not
spread systemically.
In this vaccine trial, we followed the bovine potency test
protocol described by the OIE and used by vaccine
manufacturers to test the traditional inactivated FMD
vaccines with some modifications to address the goals of
this research (Anonymous, 2004). The OIE protocol includes
three groups of no fewer than five cattle per group and a
control group of two non-vaccinated animals. The vacci-
nated groups are administered different doses of the vaccine
Rapid Communication208and all animals are challenged 3 weeks after vaccination with
10,000 BID50 of a fully virulent virus homologous to the
vaccine under test by intradermal inoculation into two sites
on the upper surface of the tongue. For the challenge to be
considered effective, both control animals must develop
lesions on at least three feet. Vaccinated animals are
protected if they do not develop lesions on the feet and
areas other than the injection sites on the tongue.
Our goal was to determine the potency of the Ad5-A24
vaccine in an emergency situation when rapid protection is
required so we have modified this protocol and in addition
only tested one dose of the vaccine. Based on these
standards, the Ad5-A24 subunit vaccine was successful.
The one animal that developed a dental pad lesion would
presumably be considered protected since the disease did
not spread systemically as shown by the absence of viremia
and lesions on the feet. Because FMDV is not thought to be
capable of entrance through intact stratified squamous
epithelium, the lesion in this area may have arisen due to
an abrasion from collection of probang samples.
In the current study, 4 of 5 cattle showed NSP antibodies
when evaluated by RIP at 28 dpc. To confirm these results,
we analyzed weekly serum samples by a 3ABC-ELISA and
all 5 vaccinated animals were positive at 28 dpc. However,
the absence of antibodies to any or all of the NSP does not
provide effective evidence that the animal has never been
infected with FMDV, as reviewed by Clavijo et al. (2004).
These results presumably indicate that although the vaccine
protected the animals from viremia and clinical disease,
there was limited replication of the challenge virus, probably
at the inoculation site, where formation of a vesicle was seen
in all animals. Replication at the inoculation site of
vaccinated animals was previously reported by others
(Alexandersen et al., 2003; Doel, 2003). In our experiment,
local viral replication was also demonstrated by the isolation
of virus from probang samples obtained from the 7 cattle
from day 1 to 7 postchallenge, where 6 or 7 samples of each
animal were positive (results not shown). It is generally
assumed that most effective vaccines do not induce sterile
immunity, but rather prevent the appearance of clinical
disease (Doel, 2003; Murphy and Chanock, 1996).
In a previous preliminary study, we inoculated two
animals with two doses of the Ad5-A24 vaccine, given 9
weeks apart and at the same dose used in this study, and
challenged the animals and one control animal 2 weeks
postboost with 105 BID50 virulent homologous virus, a 10-
fold higher challenge dose than recommended (Grubman
and Mason, 2002). The vaccinated animals developed a very
significant FMDV-specific neutralizing antibody response at
the time of challenge and after challenge were completely
protected from clinical disease, while the control animal
developed severe disease. In addition, the vaccinated animals
did not develop fever or viremia. When evaluated for NSP
antibodies at 63 days postvaccination and at 14 days
postboost, the two vaccinated animals were negative by
3ABC-ELISA and RIP. The absence of antibodies againstNSP after a second vaccination with Ad5-A24 clearly
demonstrates that animals vaccinated with this subunit
vaccine can be differentiated from infected animals. Fur-
thermore, the ability to effectively revaccinate animals 9
weeks after the initial inoculation indicates that the Ad5-
vectored approach can also be useful in vaccination
campaigns in enzootic areas where semi-annual or annual
revaccinations are required.
To control FMD outbreaks that occur in previously
disease-free countries, the induction of rapid protection is
essential. We have previously demonstrated that the admi-
nistration of type I interferon (IFN-a/h), via a Ad5-vector,
can induce sterile protection in swine when challenged with
FMDV 1–5 days postinoculation (Chinsangaram et al.,
2003; Moraes et al., 2003) and reduce and delay clinical
disease in cattle (Wu et al., 2003a). Based on these
observations, our current approach towards rapid control
of FMD incursions in disease-free countries is to use a
combination of IFN-a/h treatment to induce rapid protec-
tion and an Ad5-FMDV empty capsid vaccine to induce
specific and long-lasting immunity (Grubman, 2003).Materials and methods
Cell lines and viruses
Human 293 cells were used to generate recombinant
adenovirus and produce virus stocks. The cells were
maintained in Eagle’s minimal essential medium (MEM)
containing 10% fetal calf serum supplemented with anti-
biotics (Graham et al., 1977). Baby hamster kidney (BHK-
21) cells were used to propagate and titrate FMDVand were
maintained in BME containing 10% calf serum and 10%
tryptose phosphate broth supplemented with antibiotics.
Virus used for challenge was obtained from the vesicular
fluid of a lesion of an FMDV A24-infected bovine. The
BID50 was determined by standard methods (Henderson,
1949, 1952). Recombinant Ad5 vectors expressing the
capsid (P1-2A) of FMDVA24 Cruzeiro and the 3C protease
coding region of A12 (Ad5-A24) or VSV glycoprotein G
(Ad5-VSVG) were constructed as previously described
(Moraes et al., 2001, 2002) and purified by CsCl gradient
centrifugation (Wu et al., 2003b).
Vaccination of cattle with Ad5-A24
The cattle experiments were performed in disease-secure
isolation facilities at the Plum Island Animal Disease Center
following a protocol approved by the Institutional Animal
Use and Care Committee. Seven Holstein cattle (6–8 months
old, 450–500 lb each) were inoculated IM in the neck. Five
animals were vaccinated with 5  109 pfu/animal of Ad5-
A24. Two bovines were vaccinated with 5  109 pfu Ad5-
VSVG as controls. All animals were housed in the same
room. Sera were taken before vaccination and at 4 and 7 dpv.
Rapid Communication 209Challenge with FMDV A24
All animals were challenged at 7 dpv by intradermal
inoculation at two sites in the upper surface of the tongue
with 2 104 BID50 FMDVA24 Cruzeiro in a total of 200 Al.
Heparinized blood was collected every day for 7 dpc and
plasma samples stored at 70 -C. Serum samples were
collected at 0, 4, 7, 14, 21, and 28 dpc and aliquots stored at
70 -C. The rectal temperature of the animals was monitored
daily. The restrained animals were carefully examined in the
muzzle, inside the mouth, and feet every day for the first 10
days after challenge. Clinical scores were determined by the
following criteria: tongue lesion beyond inoculation site = 1;
mouth lesion other than tongue = 1; lesion on nostril = 1; one
lesion per foot = 1; two or more lesions per foot = 2. The
maximum score is 11. The experiment was ended at 28 dpc
and all animals were humanely euthanized.
Serology and virus titration
Sera were tested for the presence of neutralizing
antibodies against FMDV by a plaque reduction neutra-
lization (PRN) assay (Mason et al., 1997). Neutralizing
titers were reported as the serum dilution yielding a 70%
reduction in the number of plaques (PRN70). Sera were
also tested for the presence of antibodies against viral NSP
by a 3ABC indirect enzyme-linked immunosorbent assay
(3ABC ELISA) as modified from Meyer et al. (1997) and
by a RIP assay (Mayr et al., 1999). Virus titers were
determined in plasma by a standard plaque assay in BHK-
21 cells (Hierholzer and Killington, 1996).Acknowledgments
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